NCT04532866

Brief Summary

This study investigates the time course and magnitude of eight months of isolation and confinement in a spaceflight analog facility on brain changes and cognitive performance. The study also assesses the feasibility of an immersive and interactive virtual environment (VE) to enhance positive affect and mental well-being during prolonged isolation and confinement.

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
16

participants targeted

Target at below P25 for not_applicable

Timeline
Completed

Started Sep 2021

Typical duration for not_applicable

Geographic Reach
1 country

1 active site

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

August 19, 2020

Completed
12 days until next milestone

First Posted

Study publicly available on registry

August 31, 2020

Completed
1 year until next milestone

Study Start

First participant enrolled

September 14, 2021

Completed
1.1 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

October 30, 2022

Completed
1.7 years until next milestone

Study Completion

Last participant's last visit for all outcomes

June 30, 2024

Completed
Last Updated

August 30, 2023

Status Verified

August 1, 2023

Enrollment Period

1.1 years

First QC Date

August 19, 2020

Last Update Submit

August 29, 2023

Conditions

Keywords

Sensory deprivationSpaceflightSocial isolationSpatial navigation

Outcome Measures

Primary Outcomes (5)

  • Change in brain structure

    Change in gray matter (whole brain and hippocampus) using magnetic resonance imaging (MRI).

    pre-intervention, immediately after the intervention, up to 30 days after study completion

  • Change in brain function

    Change in BOLD signal using functional magnetic resonance imaging (fMRI).

    pre-intervention, immediately after the intervention, up to 30 days after study completion

  • Change in cognitive performance

    Change in reaction time, accuracy, spatial updating, path integration, visuo-spatial memory and learning, spatial orientation ability, and navigation strategy preferences using a cognitive test battery.

    pre-intervention, monthly during the intervention, immediately after the intervention, up to 30 days after study completion

  • Change in biochemical parameters

    Percent change in BDNF, IGF-1, VEGF, oxytocin, and neurofilament light chain using serum, plasma and EDTA samples.

    pre-intervention, monthly during the intervention, immediately after the intervention, up to 30 days after study completion

  • Change in stress response

    Percent change in salivary cortisol using a cotton swab system.

    pre-intervention, monthly during the intervention, immediately after the intervention, up to 30 days after study completion

Secondary Outcomes (2)

  • Biochemical parameters in response to sensory stimulation

    Baseline, monthly during the VR intervention, immediately after each VR intervention, and up to 1h after the VR intervention

  • Markers of mood and mental well-being in response to sensory stimulation

    pre-intervention, monthly during VR stimulation, monthly immediately after VR stimulation, monthly up to 1h after VR stimulation

Other Outcomes (4)

  • Correlation between changes in brain structure and function and changes in cognitive performance

    pre-intervention, monthly during the intervention, immediately after the intervention, up to 30 days after study completion

  • Correlation between changes in brain structure and function and changes in biochemical parameters

    pre-intervention, monthly during the intervention, immediately after the intervention, up to 30 days after study completion

  • Correlation between changes in cognitive performance and changes in biochemical parameters

    pre-intervention, monthly during the intervention, immediately after the intervention, up to 30 days after study completion

  • +1 more other outcomes

Study Arms (2)

Isolation and Confinement

EXPERIMENTAL

Six crew members will spend 8 months isolated and confined in the spaceflight analog NEK in Moscow.

Behavioral: Isolation and Confinement

Control Group

NO INTERVENTION

Up to ten participants matched for age, gender, and educational background undergo the same test protocol as the experimental group at identical points in time but without being isolated and confined in the NEK facility.

Interventions

Eight months of isolation and confinement in the spaceflight analog NEK in Moscow

Isolation and Confinement

Eligibility Criteria

Age28 Years - 55 Years
Sexall
Healthy VolunteersYes
Age GroupsAdult (18-64)

You may qualify if:

  • Candidates who are professionals in the aerospace industry or related fields are eligible at a lower age limit of 28
  • Height not to exceed 180 cm.
  • Willing to be confined and isolated for up to 8 months.
  • English and Russian verbal and written proficiency not lower than intermediate
  • Absence of chronic disease or psychological deviations

You may not qualify if:

  • Everybody who does not meet listed above requirements
  • Past mental, cardiovascular, musculoskeletal and/or neurovestibular disorders or diseases
  • Pronounced orthostatic intolerance or vestibular balance disorders (kinetosis)
  • Abuses of drugs, medication or alcohol
  • Claustrophobia
  • Malnutrition up to 6 months before the start of the study
  • Intake of anabolic steroids up to 6 months before study initiation
  • Metal implants or other osteosynthesis materials
  • Bisphosphonate therapy
  • Taking medication that could influence the results of the examination.
  • Taking hormonal contraceptives in the last 6 months before the start of the study
  • Menstrual disorders
  • Delivery up to 6 months before the start of studies
  • clinically manifest abnormalities in the resting ECG that preclude participation in the study
  • Hypertension (\> 130/85 mmHg)
  • +26 more criteria

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

NEK

Moscow, 123007, Russia

Location

MeSH Terms

Conditions

Social IsolationSpatial Navigation

Condition Hierarchy (Ancestors)

Social BehaviorBehaviorSpatial Behavior

Study Officials

  • Alexander C Stahn, PhD

    Charite University, Berlin, Germany

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
not applicable
Allocation
NON RANDOMIZED
Masking
NONE
Purpose
BASIC SCIENCE
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Principal Investigator

Study Record Dates

First Submitted

August 19, 2020

First Posted

August 31, 2020

Study Start

September 14, 2021

Primary Completion

October 30, 2022

Study Completion

June 30, 2024

Last Updated

August 30, 2023

Record last verified: 2023-08

Data Sharing

IPD Sharing
Will not share

Locations